[
  {
    "ts": null,
    "headline": "Labcorp Holdings Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Labcorp Holdings has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=f6ecd5b4b5bd506a58ebc6e2381271adcfaf945af07790e08f56f3abdfd7c86d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771503666,
      "headline": "Labcorp Holdings Stock: Is Wall Street Bullish or Bearish?",
      "id": 139149289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp Holdings has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=f6ecd5b4b5bd506a58ebc6e2381271adcfaf945af07790e08f56f3abdfd7c86d"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp Alzheimer’s Blood Test And Neurology Hire Spark Valuation Debate",
    "summary": "Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also appointed Dr. John H. Sampson, a leading neurologist and researcher, to its Board of Directors. Labcorp, a large player in diagnostics and central laboratory services, is moving deeper into neurology focused testing with this Alzheimer’s blood test. The test offers a less invasive option...",
    "url": "https://finnhub.io/api/news?id=3483e09f3b2b8b64ee73b95583d853f30a4cc1f349600b8e32f2260c90fd5b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771477977,
      "headline": "Labcorp Alzheimer’s Blood Test And Neurology Hire Spark Valuation Debate",
      "id": 139142657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also appointed Dr. John H. Sampson, a leading neurologist and researcher, to its Board of Directors. Labcorp, a large player in diagnostics and central laboratory services, is moving deeper into neurology focused testing with this Alzheimer’s blood test. The test offers a less invasive option...",
      "url": "https://finnhub.io/api/news?id=3483e09f3b2b8b64ee73b95583d853f30a4cc1f349600b8e32f2260c90fd5b95"
    }
  }
]